Integra LifeSciences Company Insiders
| IART Stock | USD 26.12 0.22 0.84% |
Slightly above 67% of Integra LifeSciences' corporate insiders are selling. The analysis of insiders' sentiment of trading Integra LifeSciences Holdings stock suggests that many insiders are alarmed at this time. Integra LifeSciences employs about 3.9 K people. The company is managed by 22 executives with a total tenure of roughly 54 years, averaging almost 2.0 years of service per executive, having 179.36 employees per reported executive.
| Stuart Essig Chairman Chairman of the Board |
| Kenneth Burhop President Chief Scientific Officer, Corporate Vice President |
Integra LifeSciences' Insider Buying Vs Selling
33
Selling | Buying |
Latest Trades
| 2024-12-02 | Michael J Mcbreen | Disposed 1700 @ 24.16 | View | ||
| 2024-06-18 | Josh Gottheimer | Disposed @ 29 | |||
| 2024-05-23 | Stuart Essig | Acquired 52641 @ 28.49 | View |
Monitoring Integra LifeSciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Integra LifeSciences' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Integra LifeSciences Holdings. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Integra LifeSciences' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Integra |
Integra LifeSciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Integra LifeSciences' future performance. Based on our forecasts, it is anticipated that Integra will maintain a workforce of slightly above 3950 employees by March 2025.Integra LifeSciences' latest congressional trading
Congressional trading in companies like Integra LifeSciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Integra LifeSciences by those in governmental positions are based on the same information available to the general public.
| 2024-07-09 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Integra LifeSciences Management Team Effectiveness
The company has return on total asset (ROA) of 0.0302 % which means that it generated a profit of $0.0302 on every $100 spent on assets. This is way below average. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.04 in 2025. Return On Capital Employed is likely to gain to 0.03 in 2025. At this time, Integra LifeSciences' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4.6 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 150.3 M in 2025.Net Income Applicable To Common Shares is likely to gain to about 218 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 67.2 M in 2025.
Integra LifeSciences Workforce Comparison
Integra LifeSciences Holdings is rated fourth overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 35,553. Integra LifeSciences retains roughly 3,946 in number of employees claiming about 11% of equities under Health Care industry.
Integra LifeSciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Integra LifeSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Integra LifeSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Integra LifeSciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.25 | 1 | 4 | 9,814 | 19,846 |
| 2024-09-01 | 0.3333 | 1 | 3 | 10,356 | 5,164 |
| 2024-06-01 | 6.5 | 13 | 2 | 168,443 | 239.00 |
| 2024-03-01 | 1.0345 | 30 | 29 | 387,450 | 38,578 |
| 2023-12-01 | 1.0 | 2 | 2 | 12,030 | 14,076 |
| 2023-09-01 | 5.0 | 5 | 1 | 50,620 | 1,177 |
| 2023-06-01 | 5.5 | 11 | 2 | 45,300 | 185.00 |
| 2023-03-01 | 0.8667 | 39 | 45 | 223,674 | 32,566 |
| 2022-12-01 | 2.0 | 2 | 1 | 41,406 | 279.00 |
| 2022-09-01 | 0.125 | 1 | 8 | 2,969 | 22,041 |
| 2022-06-01 | 2.25 | 9 | 4 | 27,481 | 7,549 |
| 2022-03-01 | 0.975 | 39 | 40 | 328,712 | 253,375 |
| 2021-09-01 | 0.2222 | 2 | 9 | 118,434 | 245,455 |
| 2021-06-01 | 1.4 | 21 | 15 | 77,356 | 98,223 |
| 2021-03-01 | 0.5263 | 20 | 38 | 213,484 | 1,128,261 |
| 2020-12-01 | 0.1765 | 3 | 17 | 51,976 | 324,576 |
| 2020-09-01 | 0.1 | 1 | 10 | 2,087 | 209,750 |
| 2020-06-01 | 1.1579 | 22 | 19 | 93,885 | 831,076 |
| 2020-03-01 | 1.0588 | 54 | 51 | 677,530 | 253,551 |
| 2019-09-01 | 0.48 | 12 | 25 | 323,018 | 1,172,961 |
| 2019-06-01 | 2.8 | 14 | 5 | 51,316 | 35,007 |
| 2019-03-01 | 0.831 | 59 | 71 | 366,322 | 110,036 |
| 2018-12-01 | 0.5 | 3 | 6 | 30,447 | 49,495 |
| 2018-09-01 | 0.3333 | 5 | 15 | 260,976 | 536,341 |
| 2018-06-01 | 2.1667 | 13 | 6 | 29,458 | 8,267 |
| 2018-03-01 | 0.8077 | 63 | 78 | 391,809 | 184,661 |
| 2017-12-01 | 0.1667 | 1 | 6 | 10,768 | 1,709 |
| 2017-09-01 | 1.0 | 3 | 3 | 15,050 | 1,049 |
| 2017-06-01 | 1.3333 | 20 | 15 | 471,215 | 744,353 |
| 2017-03-01 | 0.8548 | 53 | 62 | 392,326 | 148,644 |
| 2016-12-01 | 0.5714 | 4 | 7 | 46,115 | 46,318 |
| 2016-09-01 | 0.3077 | 4 | 13 | 25,210 | 59,056 |
| 2016-06-01 | 0.9091 | 20 | 22 | 248,276 | 461,629 |
| 2016-03-01 | 1.0189 | 54 | 53 | 215,146 | 21,756 |
| 2015-12-01 | 0.5 | 2 | 4 | 20,615 | 2,371 |
| 2015-06-01 | 1.0 | 16 | 16 | 226,665 | 413,997 |
| 2015-03-01 | 0.98 | 49 | 50 | 139,410 | 25,697 |
| 2014-12-01 | 0.3 | 3 | 10 | 200,000 | 404,048 |
| 2014-09-01 | 0.0556 | 1 | 18 | 300.00 | 118,500 |
| 2014-06-01 | 0.8571 | 18 | 21 | 85,089 | 159,364 |
| 2014-03-01 | 0.5366 | 22 | 41 | 349,859 | 531,343 |
| 2013-09-01 | 0.1333 | 2 | 15 | 3,594 | 71,503 |
| 2013-06-01 | 0.7 | 14 | 20 | 72,883 | 11,393 |
| 2013-03-01 | 1.5455 | 17 | 11 | 46,375 | 924,667 |
| 2012-12-01 | 0.2 | 3 | 15 | 1,691,386 | 2,869,293 |
| 2012-09-01 | 0.1429 | 1 | 7 | 12,500 | 31,085 |
| 2012-06-01 | 2.8 | 14 | 5 | 52,052 | 6,883 |
| 2012-03-01 | 2.0 | 2 | 1 | 232,716 | 1,900 |
| 2011-06-01 | 3.3333 | 10 | 3 | 33,468 | 3,661 |
| 2011-03-01 | 0.5 | 1 | 2 | 7,500 | 15,000 |
| 2010-06-01 | 5.5 | 11 | 2 | 43,182 | 1,543 |
| 2010-03-01 | 0.4 | 8 | 20 | 44,888 | 92,341 |
| 2009-03-01 | 1.0 | 2 | 2 | 103,855 | 145,450 |
| 2008-09-01 | 1.6111 | 29 | 18 | 106,234 | 77,119 |
| 2008-06-01 | 3.0 | 3 | 1 | 16,661 | 10,000 |
| 2007-09-01 | 0.7368 | 14 | 19 | 41,613 | 83,226 |
| 2007-06-01 | 11.0 | 11 | 1 | 42,999 | 10,000 |
| 2006-12-01 | 0.875 | 21 | 24 | 259,344 | 264,179 |
| 2006-09-01 | 2.0 | 2 | 1 | 25,593 | 0.00 |
| 2006-06-01 | 0.875 | 7 | 8 | 24,748 | 28,082 |
| 2006-03-01 | 0.6667 | 12 | 18 | 86,332 | 130,260 |
| 2005-12-01 | 0.1053 | 8 | 76 | 48,039 | 230,055 |
| 2005-09-01 | 0.6667 | 4 | 6 | 122,000 | 25,187 |
| 2005-06-01 | 0.3077 | 8 | 26 | 42,096 | 44,952 |
| 2005-03-01 | 2.0 | 2 | 1 | 17,630 | 10,130 |
| 2004-12-01 | 0.1212 | 20 | 165 | 215,000 | 200,000 |
| 2004-09-01 | 0.7 | 7 | 10 | 24,289 | 44,289 |
| 2004-06-01 | 1.7143 | 12 | 7 | 92,500 | 35,000 |
| 2004-03-01 | 0.0725 | 14 | 193 | 97,564 | 217,463 |
| 2003-12-01 | 2.5 | 10 | 4 | 18,347 | 9,200 |
| 2003-09-01 | 1.0 | 2 | 2 | 100,000 | 2,017 |
| 2003-06-01 | 0.1765 | 3 | 17 | 30,000 | 163,259 |
Integra LifeSciences Notable Stakeholders
An Integra LifeSciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Integra LifeSciences often face trade-offs trying to please all of them. Integra LifeSciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Integra LifeSciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jan Witte | CEO President | Profile | |
| Mojdeh Poul | CEO President | Profile | |
| Stuart Essig | Chairman of the Board | Profile | |
| Kenneth Burhop | Chief Scientific Officer, Corporate Vice President | Profile | |
| Eric Schwartz | Corporate Vice President General Counsel, Secretary | Profile | |
| Robert Davis | President of Specialty Surgical Solutions and Corporate VP | Profile | |
| Jeffrey Mosebrook | Principal Accounting Officer, Vice President Corporate Controller | Profile | |
| Carrie Anderson | CFO and Principal Financial Officer, Corporate Vice President | Profile | |
| Lea Knight | Executive CFO | Profile | |
| Eric JD | Chief VP | Profile | |
| Ruth Fleming | Vice Marketing | Profile | |
| Mathieu Aussermeier | Investor Finance | Profile | |
| Maria Platsis | Sr Devel | Profile | |
| William Compton | Chief VP | Profile | |
| Chantal VeillonBerteloot | Executive Officer | Profile | |
| Susan Krause | Corporate Officer | Profile | |
| Stuart Hart | Corporate Officer | Profile | |
| Mark Jesser | Corporate Officer | Profile | |
| Laurene Isip | Vice Relations | Profile | |
| Michael McBreen | Executive Surgical | Profile | |
| Jessica Smith | Corporate Officer | Profile | |
| Stephen Leonard | Corporate Chain | Profile |
About Integra LifeSciences Management Performance
The success or failure of an entity such as Integra LifeSciences often depends on how effective the management is. Integra LifeSciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Integra management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Integra management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.04 |
Please note, the imprecision that can be found in Integra LifeSciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Integra LifeSciences Holdings. Check Integra LifeSciences' Beneish M Score to see the likelihood of Integra LifeSciences' management manipulating its earnings.
Integra LifeSciences Workforce Analysis
Traditionally, organizations such as Integra LifeSciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Integra LifeSciences within its industry.Integra LifeSciences Manpower Efficiency
Return on Integra LifeSciences Manpower
| Revenue Per Employee | 390.7K | |
| Revenue Per Executive | 70.1M | |
| Net Income Per Employee | 17.2K | |
| Net Income Per Executive | 3.1M | |
| Working Capital Per Employee | 190.3K | |
| Working Capital Per Executive | 34.1M |
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.